Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebreltinib + Andamertinib in EGFR-mutated, MET-amplified Advanced NSCLC
NCT06343064Phase 2Recruiting
- Sponsor
- Avistone Biotechnology Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of vebreltinib, andamertinib in non-small cell lung cancer (NSCLC), sponsored by Avistone Biotechnology Co., Ltd.. Started Jun 2023; status: recruiting.
02
Drugs
vebreltinibandamertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06343064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06343064.